Division of Coronary Artery Disease and Intensive Cardiac Care, Hôpital Européen Georges Pompidou, Assistance Publique des Hôpitaux de Paris, Université Paris Descartes, Paris, France.
Int J Cardiol. 2013 Jun 5;166(1):106-10. doi: 10.1016/j.ijcard.2011.10.008. Epub 2011 Nov 10.
There are limited data on the safety and efficacy of low molecular weight heparin (LMWH) in elderly patients with acute myocardial infarction (AMI).
We aimed to compare LMWH with unfractioned heparin (UFH) in the management of AMI in elderly patients. FAST-MI is a nationwide registry carried out over a 1-month period in 2005, including consecutive patients with AMI admitted to intensive care unit <48 h from symptom onset in 223 participating centers. We assessed the impact of LMWH on bleeding, the need for blood transfusion and one-year survival in elderly patients (≥ 75 years).
963 patients treated with heparin were included (mean age 82 ± 5 years; 51% women; 42.5% ST-elevation myocardial infarction). Major bleeding (2.4% vs. 6.1%, P=0.004) and blood transfusions (4.6% vs. 9.7%, P=0.002) were significantly less frequent with LMWH compared with the UFH, a difference that persisted after multivariate adjustment (OR=0.41, 95% CI: 0.20-0.83 and OR=0.49, 95% CI: 0.28-0.85, respectively). One-year survival and stroke and reinfarction-free survival were also significantly higher with LMWH compared with UFH (OR=0.66, 95% CI: 0.50-0.85 and OR=0.71, 95% CI: 0.56-0.91, respectively). In two cohorts of patients matched on a propensity score for getting LMWH and with similar baseline characteristics (328 patients per group), major bleeding and transfusion were significantly lower while one-year survival was significantly higher in patients receiving LMWH.
The present data show that in elderly patients admitted for AMI, use of LMWH is associated with less bleeding, less need for transfusion, and higher survival, compared with the use of UFH.
关于在急性心肌梗死(AMI)老年患者中使用低分子肝素(LMWH)的安全性和疗效的数据有限。
我们旨在比较 LMWH 与未分级肝素(UFH)在老年 AMI 患者中的管理效果。FAST-MI 是一项全国性注册研究,于 2005 年在 223 个参与中心进行了为期 1 个月的研究,纳入了从症状发作到入重症监护病房时间<48 小时的连续 AMI 患者。我们评估了 LMWH 对老年患者(≥75 岁)出血、输血需求和一年生存率的影响。
共纳入 963 例接受肝素治疗的患者(平均年龄 82±5 岁;51%为女性;42.5%为 ST 段抬高型心肌梗死)。与 UFH 相比,LMWH 组的大出血(2.4% vs. 6.1%,P=0.004)和输血(4.6% vs. 9.7%,P=0.002)发生率明显较低,这种差异在多变量调整后仍然存在(OR=0.41,95%CI:0.20-0.83 和 OR=0.49,95%CI:0.28-0.85)。与 UFH 相比,LMWH 组一年生存率和无卒中和再梗死生存率也明显较高(OR=0.66,95%CI:0.50-0.85 和 OR=0.71,95%CI:0.56-0.91)。在两个倾向评分匹配接受 LMWH 治疗的患者队列中(每组 328 例),与 UFH 相比,大出血和输血明显减少,而接受 LMWH 治疗的患者一年生存率明显较高。
目前的数据表明,在因 AMI 入院的老年患者中,与 UFH 相比,使用 LMWH 可减少出血、减少输血需求,并提高生存率。